Mostrando las entradas para la consulta miles white ordenadas por relevancia. Ordenar por fecha Mostrar todas las entradas
Mostrando las entradas para la consulta miles white ordenadas por relevancia. Ordenar por fecha Mostrar todas las entradas

martes, 24 de marzo de 2009

Feria de despropósitos: Abbott en los "tiempos de crisis"...o la "penuria" llega para Miles White....



Miles White es el CEO de Abbott.



Cuando publicamos “Cuanto ganan los que más ganan” ocupaba la primera posición con un paquete salarial de 33.400.000$ (Treinta y tres punto cuatro millones de dólares) anuales.


Ahora, por eso de la crisis, de la mala situación económica y “decencia” pública…han decidido hacerle una reducción
“sensible de salario.


En lo sucesivo tan solo ganará 28.300.000$ (Veintiocho punto tres millones de dólares). Vamos que, cuando hay que apretar el cinturón…se aprieta el cinturón.


Miles D. White Age 54 Director since 1998

Chairman of the Board and Chief Executive Officer, Abbott Laboratories

Mr. White has served as Abbott's chairman of the board and chief executive officer since 1999. He served as an executive vice president of Abbott from 1998 to 1999, as senior vice president, diagnostics operations from 1994 to 1998, and as vice president, diagnostics systems operations from 1993 to 1994. Mr. White joined Abbott in 1984. He received both his bachelor's degree in mechanical engineering and M.B.A. degree from Stanford University. He serves on the board of trustees of The Culver Educational Foundation, The Field Museum in Chicago, and Northwestern University. He serves as a director of Motorola Inc.



Y a Miles White, al leer esta noticia…,se le puso la “cara en blanco”



martes, 31 de marzo de 2009

Pharma tiene dos "Reyes de la jungla": Levinson (Genentech) y White (Abbott)

Un grupo de editores de Barron´s , después de conversar con inversores, analistas, ejecutivos y otros elaboró la lista de los 30 ejecutivos más destacados.

En ella aparecen dos de la industria farmacéutica:Art Levinson de Genetech y Miles White de Abbott.




Los dos han sido noticia en PHARMACOSERÍAS, Art Levinson por la "Historia interminable" de las negociaciones con Roche, Miles White por su "escandaloso" paquete salarial...en estos tiempos de "crisis"
.
Estos son los comentarios de la revista y los perfiles profesionales:

"The final list is made up of chief executive officers from around the world who are doing outstanding jobs of keeping their companies out of trouble and on course. That means conservative financial management, a strong focus on the customer and relentless innovation.

The roster includes no fewer than 12 new names. Jeff Bezos of Amazon.com, for instance, has transformed his company from an online bookseller to one of the world's top retailers, with a true hot product in its Kindle wireless e-book reader. Under Jim Skinner, McDonald's started growing again as the company capitalized on healthier foods like salads, while not ignoring its core customers who crave Big Macs. In financial services, few leaders stand taller than JPMorgan Chase's Jamie Dimon, who has avoided major mishaps and become the go-to guy for regulators looking to unload crippled companies like Bear Stearns and Washington Mutual."




Art Levinson
Genentech, CEO since ’95
Why: Labs of lucre.
After 13 years as chief of the
biotechnology trailblazer,
Art Levinson extracted a multiple
of 25 times earnings from Roche
as the Swiss giant agreed this
month to pay $95 a share for the
44% of Genentech it doesn’t already
own.

That is double the biotech industry

multiple and a tribute to
the research productivity that
Levinson famously cultivated. Genentech
got more biotech treatments
approved than any rival
and has more than 100 clinical trials
under way. Profit has grown
at a 40% rate in the past five
years, on rising sales of cancer
treatments like Rituxan, Herceptin
and Avastin. Levinson’s company is one of the country’s biggest
sellers of cancer drugs, in part thanks to the high prices
it commands for its innovations.
Neither Roche nor Genentech has announced Levinson’s
role in Genentech after it becomes a wholly owned part of
Roche, but the Swiss company said it hoped to retain him
and other Genentech leaders. Roche will adopt the Genentech
name for all U.S. operations. —BillAlpert

martes, 13 de julio de 2010

Cuanto ganan los que más ganan...2009 (cont.)

The major trend in 2009 was the mega-merger, which helped propel former Schering-Plough CEO Fred Hassan to the top of this year's list. With the help of a $33 million golden handshake, Hassan bypassed perennial top dogs Bill Weldon (Johnson & Johnson) and Miles White (Abbott) as the highest-paid CEO in Pharma.

Novartis' Daniel Vasella moved up three places to the number four spot this year, but it will be his last appearance on our CEO pay list. Vasella stepped down as chief of Novartis in January, and was replaced by Joe Jimenez. To discover more details for yourself--or to find out what your boss is making--take a look at the list below. (Ver)





  • 1. Fred Hassan - Schering-Plough - $49.65M




2. Bill Weldon - Johnson & Johnson - $30M





  • 3. Miles White - Abbott Laboratories - $26.2M


  • 4. John Lechleiter - Eli Lilly - $20.9M







  • 5. Daniel Vasella - Novartis - $20.24M




  • 6. Jim Cornelius - Bristol-Myers Squibb - $18.2M





  • 7. Richard Clark - Merck - $16.8M





  • 8. Robert Coury - Mylan - $16M







  • 9. Jeffrey Kindler - Pfizer - $14.8M



  • 10. Frank Baldino - Cephalon - $11.1M



Ver anteriores

"De l´ home mira sempre les mans..." (Raimon)

jueves, 18 de noviembre de 2010

Cuanto ganan los que más ganan 2010 (I)

Ver...

Menos mal que vamos mal...



Click sobre imagen para ampliar

El primer ejecutivo de una "Big Pharma" es William Weldon, de Johnson&Johnson con 19.8 millones de $
En el número 25 aparece Miles White de Abbot con 18.7 millones de $


Y acá los de las "Big Pharma" que aparecen mezclados con los de Salud...
Jim Cornelius jubilado reciente como CEO en BMS aparece el 36º 16.7 millones de $ en el 41º John Lechleiter de Eli Lilly y el 50º es Jeff Kindler de Pfizer.


Cuanto ganan los que más ganan...2009 (cont.)

domingo, 10 de agosto de 2008

Cuanto ganan los que más ganan...

Algo que, a todos ellos, se les "va de las manos..."


Top 17 Paychecks in Big Pharma

1. Miles White - Abbott - $33.4M

2. Fred Hassan - Schering-Plough - $30.1M

3. Bill Weldon - Johnson & Johnson - $25.1M

4. Bob Essner - Wyeth - $24.1M

5. Robert Parkinson - Baxter - $17.6M


6. Daniel Vasella - Novartis - $15.5M

7. Richard Clark - Merck - $14.5M

8. Frank Baldino - Cephalon - $13.5M

9. Sidney Taurel - Eli Lilly - $13M

10. Jeff Kindler - Pfizer - $12.6M

11. Jim Cornelius - Bristol-Myers Squibb - $11.3M

12. Franz Humer - Roche - $11.1M

13. Robert Coury - Mylan - $8.5M

14. Jean-Pierre Garnier - GlaxoSmithKline - $6M

15. Werner Wenning - Bayer - $4.77M

16. David Brennan - AstraZeneca - $4.3M

17. Gerard Le Fur - Sanofi-Aventis - $3.27M




Uffffffff...y pensar que algunos de ellos (Fred Hassan, Bob Essner y Daniel Vasella) fueron mis compañeros años atrás...

Y yo, acá...dándole al Blog...

incluso fines de semana..
.



Hay algunas personas que no estan tan de acuerdo con esta situación ...


y se quejan...:


"And everyone wonders why drugs cost so much?!"

"The earnings are obscene!"

"Where have all the leaders gone? In a time when big pharma is leading the corporate pack in losses and reduced shareholder value executives continue to be exempt from accountability for the poor performance of their corporation. Instead of finding ways to increase revenues and and grow the bottom line they are getting fat payouts for cost cutting through layoffs and cost efficiencies."

martes, 3 de mayo de 2011

Cuanto ganan los que más ganan...2010


"De l´ home mira sempre les mans..."
Raimon


Top 10 Pharma CEO salaries of 2010


By Liz Hollis and Erica Teichert

Welcome to our annual look at the biggest CEO in the pharma industry. Despite a year fraught with manufacturing issues and drug recalls, Johnson & Johnson CEO Bill Weldon takes the top spot, with $28.7 million in 2010 pay. And Novartis' Daniel Vasella grabs the number two spot thanks to a lucrative golden handshake.
Next year we'll have to say goodbye to a few familiar faces that are making their final appearance on this list. Pfizer's Jeff Kindler won't be back next year, nor will Vasella or Richard Clark of Merck. All of these CEOs will be replaced by new executives that will appear on the list. For example, Ian Read, Pfizer's new CEO, earned more than $17 million last year, even though he didn't become CEO until Dec. 5. George Scangos, formerly of Exelixis and now Biogen Idec CEO, was paid $9.4 million last year--and he didn't come on board until more than halfway through the year.
Others are waiting, too. Allergan's David Pyott ($12.7 million), Bristol-Myers Squibb's Lamberto Andreotti ($11.8 million) and Baxter's Robert Parkinson ($11.5 million) were close to making the list. Click below to get all the details on the top 10 highest paid biotech and pharma CEOs of 2010.




01. Bill Weldon - J&J - $28.7M (2º $30)







02. Daniel Vasella - Novartis - $27M (5º $20.24)






03. Miles White - Abbott- $25.6M (3º $26.2)






04. Jeffrey Kindler - Pfizer- $24.7M (9º $14.8)






05. Richard Clark - Merck - $24.6M (7º $16.8)







06. Robert Coury - Mylan - $22.9M (8º $16)







07. Kevin Sharer - Amgen - $21.1M






08. James Mullen - Biogen Idec - $20M








09. John Lechleiter - Eli Lilly - $16.5M (4º $20.9)








10. John Martin - Gilead Sciences - $14.2M




(Entre paréntesis año anterior)

No dejes de ver:


Cuanto ganan los que más ganan 2010 (I)